Redcare Pharm Br
RDC
EUR
STOCK MARKET:
ETR
Open
 
...
Large gap with delayed quotes
Last quote
05/12/2026 - 10:30:34
Bid
05/12/2026 - 10:33:40
Bid
Volume
Ask
05/12/2026 - 10:31:45
Ask
Volume
45.94
-1.30 ( -2.75% )
45.88
116
45.96
2
More information
Analysis by TheScreener
08.05.2026
Evaluation Slightly negative  
Interest Weak  
Sensibility High  
Analysis date: 08.05.2026
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 01.05.2026.
Interest
  Weak
Two stars since 08.05.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 31.03.2026 at a price of 37.24.
Evaluation
  Undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
  Negative
 
The dividend-adjusted forty day technical trend is negative since 08.05.2026.
4wk Rel Perf
  20.04%
 
The four-week dividend-adjusted overperformance versus STOXX600 is 20.04%.
Sensibility
  High
The stock has been on the high-sensitivity level since 27.05.2025.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 2.12%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.45%.
Mkt Cap in $bn
  1.07
With a market capitalization <$2bn, REDCARE PHARMACY is considered a small-cap stock.
G/PE Ratio
  1.92
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  24.08
The estimated PE is for the year 2028.
LT Growth
  46.26%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  10
Over the last seven weeks, an average of 10 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  223
For 1% of index variation, the stock varies on average by 2.23%.
Correlation
  0.43
43.47% of stock movements are explained by index variations.
Value at Risk
  21.77
The value at risk is estimated at EUR 21.77. The risk is therefore 49.29%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  03.11.2017